Overview

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

Status:
Withdrawn
Trial end date:
2017-04-20
Target enrollment:
Participant gender:
Summary
This study assesses the pharmacokinetics and safety of the new antifungal F901318 in AML patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
F2G Biotech GmbH
F2G Ltd.
Collaborator:
University Hospital of Cologne
Treatments:
Caspofungin
Echinocandins
Olorofim